Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB4 | Q15303 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5586127 | 0.94 | KDR (0.43) | ERBB4KDREPHB4TEKEGFR | |
| SCHEMBL5586002 | 0.93 | KDR (0.43) | ERBB4KDREPHB4TEKEGFR | |
| SCHEMBL5592592 | 0.93 | KDR (0.45) | ERBB4KDREPHB4TEKMAPT | |
| SCHEMBL5585975 | 0.92 | KDR (0.43) | ERBB4KDREPHB4TEKEGFR | |
| SCHEMBL5586052 | 0.92 | KDR (0.44) | ERBB4KDREPHB4TEKMAPT | |
| SCHEMBL5585926 | 0.92 | KDR (0.44) | ERBB4KDREPHB4TEKMAPT | |
| SCHEMBL5586136 | 0.92 | HCK (0.43) | ERBB4KDREPHB4TEKEGFR | |
| SCHEMBL5592851 | 0.91 | EPHB4 (0.45) | KDREPHB4TEKMAPTUSP2 | |
| SCHEMBL9885375 | 0.91 | KDR (0.43) | ERBB4KDREPHB4TEKEGFR | |
| SCHEMBL5592635 | 0.91 | KDR (0.43) | ERBB4KDREPHB4TEKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | claimed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | UCK2, CHUK, AXL | ERBB4 85/4885KDR 72/4885EPHB4 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.